187 related articles for article (PubMed ID: 31614430)
1. Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections.
Lai CC; Chen CC; Tang HJ
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31614430
[TBL] [Abstract][Full Text] [Related]
2. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
[TBL] [Abstract][Full Text] [Related]
4. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
Petty LA; Henig O; Patel TS; Pogue JM; Kaye KS
Infect Drug Resist; 2018; 11():1461-1472. PubMed ID: 30254477
[TBL] [Abstract][Full Text] [Related]
5. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
6. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Wunderink RG; Giamarellos-Bourboulis EJ; Rahav G; Mathers AJ; Bassetti M; Vazquez J; Cornely OA; Solomkin J; Bhowmick T; Bishara J; Daikos GL; Felton T; Furst MJL; Kwak EJ; Menichetti F; Oren I; Alexander EL; Griffith D; Lomovskaya O; Loutit J; Zhang S; Dudley MN; Kaye KS
Infect Dis Ther; 2018 Dec; 7(4):439-455. PubMed ID: 30270406
[TBL] [Abstract][Full Text] [Related]
7. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
Shoulders BR; Casapao AM; Venugopalan V
Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
[TBL] [Abstract][Full Text] [Related]
8. Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date.
Herald F; Burgos RM
Infect Drug Resist; 2023; 16():555-568. PubMed ID: 36726388
[TBL] [Abstract][Full Text] [Related]
9. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Roilides E; Ashouri N; Bradley JS; Johnson MG; Lonchar J; Su FH; Huntington JA; Popejoy MW; Bensaci M; De Anda C; Rhee EG; Bruno CJ
Pediatr Infect Dis J; 2023 Apr; 42(4):292-298. PubMed ID: 36689671
[TBL] [Abstract][Full Text] [Related]
13. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
14. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
[TBL] [Abstract][Full Text] [Related]
15. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Patel TS; Pogue JM; Mills JP; Kaye KS
Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
[TBL] [Abstract][Full Text] [Related]
16. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
Wu G; Cheon E
Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
18. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
19. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
